Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 14/20 | 0.75 |
| ▸ | DDB1 | Q16531 | 12/20 | 0.75 |
| ▸ | STAT3 | P40763 | 2/20 | 0.64 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.61 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.61 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.61 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.61 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.61 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.61 |
| ▸ | TNF | P01375 | 1/20 | 0.58 |
| ▸ | IL1B | P01584 | 1/20 | 0.58 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.58 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.58 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | SNCA | P37840 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17859029 | 0.93 | CRBN (0.73) | CRBNDDB1STAT3HDAC1HDAC6 | |
| SCHEMBL29622145 | 0.93 | CRBN (0.73) | CRBNDDB1STAT3HDAC1HDAC6 | |
| SCHEMBL23796444 | 0.91 | CRBN (0.70) | CRBNDDB1STAT3HDAC1HDAC6 | |
| SCHEMBL18476413 | 0.91 | CRBN (0.78) | CRBNDDB1STAT3HDAC1HDAC6 | |
| SCHEMBL26320196 | 0.91 | STAT3 (0.76) | CRBNDDB1STAT3HDAC1HDAC6 | |
| SCHEMBL29622126 | 0.90 | STAT3 (0.71) | CRBNDDB1STAT3HDAC1HDAC6 | |
| SCHEMBL17873757 | 0.90 | CRBN (0.69) | CRBNDDB1STAT3HDAC1HDAC6 | |
| SCHEMBL17859033 | 0.90 | STAT3 (0.71) | CRBNDDB1STAT3HDAC1HDAC6 | |
| SCHEMBL29622415 | 0.90 | CRBN (0.84) | CRBNDDB1STAT3HDAC1HDAC6 | |
| SCHEMBL24377001 | 0.90 | CRBN (0.84) | CRBNDDB1STAT3HDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11787778-B2 | Bi-functional compounds and methods for targeted ubiquitination of androgen receptor | MONTELINO THERAPEUTICS, INC. (US) | 2023-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11787778-B2 | Bi-functional compounds and methods for targeted ubiquitination of androgen receptor | AR, ADRM1, PSMA3 | CRBN 256/4885DDB1 2125/4885STAT3 3200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.